The range in doses was chosen from data published on bLf efficacy against anemia of inflammation on hereditary thrombophilic pregnant women with high levels of serum IL-6 (100–200 mg two times a day) [40,51] as well as on COVID-19 patients (200 mg five times a day) [33]. Here, IL6 is linked to anemia (phenotype).